WITNESSETHSettlement Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
ALTERITY THERAPEUTICS LIMITED American Depositary Shares each representing 600 fully paid Ordinary Shares Sales AgreementSales Agreement • February 15th, 2024 • Alterity Therapeutics LTD • Pharmaceutical preparations • New York
Alterity Therapeutics Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Deposit Agreement Dated as of March 23, 2001Deposit Agreement • December 21st, 2007 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • October 13th, 2016 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
Prana Biotechnology Ltd, a corporation incorporated under the laws of the state of Victoria, Australia (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) and JonesTrading Institutional Services LLC (“JonesTrading”, each of FBR and JonesTrading, individually an “Agent” and collectively, the “Agents”), as follows:
PRANA BIOTECHNOLOGY LTD American Depositary Shares each representing 10 fully paid Ordinary Shares At-The-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • July 13th, 2011 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
Prana Biotechnology Ltd, a corporation incorporated under the laws of the state of Victoria, Australia (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), as follows:
March 23, 2001Deposit Agreement • August 28th, 2006 • Prana Biotechnology LTD • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 13th, 2020 • Alterity Therapeutics LTD • Pharmaceutical preparations • New York
This Agreement is made pursuant to each Confirmation Letter, dated as of the date hereof, between A.G.P./Alliance Global Partners, as U.S. Selling Agent for a private placement of ordinary shares and options of the Company, and each Purchaser (the “Confirmation Letters”). Capitalized terms used and not otherwise defined herein that are defined in the Confirmation Letters shall have the meanings given such terms in the Confirmation Letters.
Project AgreementProject Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
EXHIBIT 4.20 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement"), dated as of July 1, 2004, between Prana Biotechnology Limited, an Australian corporation (the "Company") with its principal offices at Suite 2, 1233 High Street, Armadale,...Employment Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENTAt Market Issuance Sales Agreement • November 8th, 2017 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
Prana Biotechnology Ltd (the “Company”), B. Riley FBR, Inc. (successor by merger to FBR Capital Markets & Co.) (“B. Riley FBR”) and JonesTrading Institutional Services LLC (“JonesTrading” and together with B. Riley FBR, the “Agents”) are parties to that certain At Market Issuance Sales Agreement dated October 13, 2016 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows (to be effective as set forth in paragraph 6 below):
Master Services AgreementMaster Services Agreement • August 26th, 2015 • Prana Biotechnology LTD • Pharmaceutical preparations • Delaware
This Master Services Agreement (this “Agreement”) is made and entered into as of the date of the last party to sign (the “Effective Date”) between Certara, L.P., a Delaware limited partnership, via its branch, Certara, L.P. Sucursal em Portugal (hereinafter “Certara Portugal”), and Prana Biotechnology Ltd ACN 080 699 065, an Australian public company with its principal office at Level 2, 369 Royal Parade, Parkville, Victoria 3052 Australia (hereinafter “Customer”).
WORK AUTHORISATION Reference: WA002 (PBT2-204)Work Authorisation • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations
This Work Authorisation is between Prana Biotechnology Limited of Level 2, 369 Royal Parade, Parkville, VIC 3052, Australia (hereinafter “Customer”) and INCResearch Australia Pty Limited ACN 080 425 387 & ABN 67 080 425 387, 124 Lipson Street, Port Adelaide 5015 SA (hereinafter “INC”) and relates to the Master Services Agreement dated 28th September 2011, (the “Master Agreement”). Pursuant to the Master Agreement, INC has agreed to provide certain services in accordance with written work authorisations, such as this one, entered into from time-to-time describing such services.
EMPLOYMENT AGREEMENTEmployment Agreement • September 29th, 2006 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of date of signing between Prana Biotechnology Limited, an Australian corporation (the “Company”) with its principal offices at Level 2, 369 Royal Parade, Parkville, Victoria, Australia, and Ross Murdoch (the “Executive”), residing at 53 Kingston Street, Hampton, 3188, Victoria, Australia.
PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENTProcess Development and Manufacturing Agreement • September 24th, 2009 • Prana Biotechnology LTD • Pharmaceutical preparations • England
This PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT (hereinafter “Agreement”) is made by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2,369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at 7-1-27 Ameerpet Hyderabad 500 016 India.
EXHIBIT 4.6 Second Amendment to Exchange License Agreement, dated January 1st 2001 ("2001 License Agreement") between The General Hospital Corporation ("General") and Prana Biotechnology Limited ("Prana") Whereas General has exclusively licensed...Exchange License Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations
LOGO] AusIndustry(TM) R&D Start Program Grant Agreement Particular Conditions - ------------------------------------------------------------------------------- Parties ----------------------------------------------------------------------- ---------R&d Start Grant Agreement • September 28th, 2004 • Prana Biotechnology LTD • Pharmaceutical preparations
FIFTH RESEARCH FUNDING AND INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT BETWEEN UNIVERSITY OF MELBOURNE AND PRANA BIOTECHNOLOGY LTD (ABN 37 080 699 065)Research Funding and Intellectual Property Assignment Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
THE UNIVERSITY OF MELBOURNE [ABN 84 002 705 224] of Parkville, Victoria 3010, a body politic and corporate pursuant to the provisions of the University of Melbourne Act 2009 (Vic) (University)
EMPLOYMENT AGREEMENTEmployment Agreement • December 21st, 2005 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of 15 June, 2005, between Prana Biotechnology Limited, an Australian corporation (the “Company”) with its principal offices at Level 2, 369 Royal Parade, Parkville, Victoria, Australia, and Geoffrey Kempler (the “Executive”), residing at 19 Crotonhurst Avenue North Caulfield 3161, Victoria, Australia.
Master Services AgreementMaster Services Agreement • October 4th, 2016 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
Prana Biotechnology Ltd ACN 080 699 065 of Level 2, 369 Royal Parade, Parkville Victoria Australia 3052 (Prana) (each a party and collectively, the parties)
MANUFACTURING SERVICES AGREEMENT FOR PBT2 HCI SUPPLYManufacturing Services Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • London
This MANUFACTURING SERVICES AGREEMENT (hereinafter called “Agreement”) is made on this 19 day of August, 2013 by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2,369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at # 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Andhra Pradesh, India.
WORK ORDER INC Research Project # 1000504 Protocol # PBT2-203Work Order • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations
This Work Order (hereinafter “Work Order”) is between Prana Biotechnology Limited (hereinafter “Sponsor”) with principal offices located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015 Australia and relates to the Master Services Agreement effectively dated 22nd September 2011 which expressly incorporates this Work Order hereto by reference into the Master Services Agreement. Pursuant to the Master Services Agreement, INC Research has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time to time describing such services.
Amendment No. 2 to At-The-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • November 26th, 2014 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
MASTER SERVICES AGREEMENT FOR PROVISION OF CLINICAL RESEARCH SERVICES Between INCResearch Australia Pty Limited (ABN 67 080 425 387) of 124 Lipson Street, Port Adelaide, South Australia 5015, Australia (INC) And Prana Biotechnology Limited (ABN...Master Services Agreement • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
INTRODUCTION The Customer has requested and INC has agreed to provide the Services to the Customer. In consideration for the provision of the Services the Customer has agreed to pay INC the Services Fee. OPERATIVE CLAUSES PART 1 – PRELIMINARY 1. Definitions In this Agreement: 1.1 “Address” means the addresses of the Customer and INC specified in Item 3 of Schedule 1, or such other address as may be notified; 1.2 “Affiliates” means a related body corporate within the meaning of the Corporations Act (Cth) 2001; 1.3 “Business Day” means any day except a Saturday or a Sunday or other public holiday in South Australia; 1.4 “Business Records” means a record of: 1.4.1 the functions, decisions and meetings of the board of the Customer; 1.4.2 the conduct of the Customer’s Operations; 1.4.3 the outgoings in respect of the Customer’s Operations; 1.4.4 all marketing, advertising or promotions conducted by the Customer; and 1.4.5 all other information kept in respect of the Customer’s Operations as
Amendment 14 to Agreement dated 26th Dec’08 signed by and betweenAmendment 14 to Agreement Dated 26th Dec’08 • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations
This amendment will include the following additional and amended clauses in the above mentioned Agreement (plus amendments) and will be in effect from 18 September 2012.
WORK ORDERWork Order • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations
This Work Order (hereinafter “Work Order”) is between Prana Biotechnology Limited (hereinafter “Sponsor”) with principal offices located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015 Australia and relates to the Master Services Agreement effectively dated 22nd September 2011 which expressly incorporates this Work Order hereto by reference into the Master Services Agreement. Pursuant to the Master Services Agreement, INC Research has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time to time describing such services.
Amendment 1 to Agreement dated 19th Aug’13 signed by and between Dr. Reddy’s Laboratories Limited Bollaram Road, Miyapur, Hyderabad 500 049 India (Hereinafter referred to as “Dr. Reddy’s”) and Prana Biotechnology Ltd Level 2,369 Royal Parade,...Amendment 1 to Agreement • November 3rd, 2014 • Prana Biotechnology LTD • Pharmaceutical preparations
This amendment will include the following amended clauses in the above mentioned agreement and will be in effect from 26th September 2013.
D3 MEDICINE LLC MASTER SERVICES AGREEMENTMaster Services Agreement • August 26th, 2015 • Prana Biotechnology LTD • Pharmaceutical preparations • Victoria
This Master Services Agreement (this “Agreement”), effective 17 March, 2015 (the “Effective Date”), is entered into by and between d3 Medicine LLC, a limited liability company having offices at 4 Century Drive, 2nd Floor, Parsippany, NJ 07054, United States of America (“d3”) and Prana Biotechnology Ltd ACN 080 699 065, a limited liability company having offices at Level 2, 369 Royal Parade, Parkville Victoria 3052 (“Client”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). In consideration of the covenants and conditions contained herein, the Parties hereby agree to the following:
CHANGE ORDER N°1 to Work Order #1002213Change Order • November 3rd, 2014 • Prana Biotechnology LTD • Pharmaceutical preparations
This Change Order number 1 to Work Order #1002213 (hereinafter “Change Order”) is made and entered into as of the date of last signature (hereinafter “Effective Date”) by and between Prana Biotechnology Limited (hereinafter “Sponsor”) with an office located at Level 2, 369 Royal Parade, Parkville VIC 3052 Australia and INCResearch Australia Pty Limited, together with its parent company, subsidiaries and legal affiliates (hereinafter “INC Research”) with offices located at 124 Lipson Street, Port Adelaide SA 5015, Australia.
AMENDMENT to the Clinical Trial Agreement between Prana Biotechnology Limited and The University of RochesterClinical Trial Agreement • November 3rd, 2014 • Prana Biotechnology LTD • Pharmaceutical preparations
WHEREAS, The University of Rochester (“Institution”) and Prana Biotechnology Limited (“Sponsor”) have entered into a Clinical Trial Agreement dated October 7, 2011 relating to clinical trial services with regard to the product PBT2 (“Agreement”), and
AGREEMENTGeneral Services Agreement • November 9th, 2010 • Prana Biotechnology LTD • Pharmaceutical preparations
This Agreement is made and dated as of June 23, 2010 (this “Agreement”) between Quintiles Limited (“Quintiles”) and Prana Biotechnology Limited (“Prana”). Each of Quintiles and Prana may be referred to herein as a “Party” and collectively as the “Parties.”
Clinical Research Support AgreementClinical Research Support Agreement • October 4th, 2012 • Prana Biotechnology LTD • Pharmaceutical preparations
The General Hospital Corporation d/b/a Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, United States of America (MGH)
Prana Biotechnology Limited Level 2, 369 Royal Parade, ParkvilleLetter Agreement for Clinical Trial Services • October 22nd, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations
AMENDMENT NO. 2 TO AT MARKET ISSUANCE SALES AGREEMENTAt Market Issuance Sales Agreement • December 16th, 2020 • Alterity Therapeutics LTD • Pharmaceutical preparations • New York
Alterity Therapeutics Limited (formerly Prana Biotechnology Ltd) (the “Company”), B. Riley Securities, Inc. (formerly B. Riley FBR, Inc. (successor by merger to FBR Capital Markets & Co.)) (“B. Riley”) and JonesTrading Institutional Services LLC (“JonesTrading” and together with B. Riley, the “Agents”) are parties to that certain At Market Issuance Sales Agreement dated October 13, 2016, as amended on November 8, 2017 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:
Amendment 1.3 to Agreement dated 26th Dec ’08 signed by and between Dr. Reddy’s Laboratories Limited Bollaram Road, Miyapur, Hyderabad 500 049 India (Hereinafter referred to as “Dr. Reddy’s”) And Prana Biotechnology Ltd Level 2, 369 Royal Parade,...Amendment to Agreement Dated 26th Dec ’08 • October 4th, 2012 • Prana Biotechnology LTD • Pharmaceutical preparations
This amendment will include the following additional and amended clauses in the above mentioned Agreement (plus amendments) and will be in effect from 14 February 2012 onwards.
Amendment No. 1 to At-The-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • August 30th, 2013 • Prana Biotechnology LTD • Pharmaceutical preparations • New York
